Year: 2023 Title: ONWARDS 1 Subtitle: Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin Type of Trial: Randomized, open-label, treat-to-target phase 3a trial Objective: To investigate the efficacy and long-term safety of once-weekly insulin icodec … Read More
type 2 diabetes
CAROLINA Trial: Linagliptin vs. Glimepiride in T2DM
Year: 2019 Title: CAROLINA TRIAL Subtitle: Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes Type of Trial: An International, Randomised, Parallel Group, Double Blind Trial Objective: To assess cardiovascular outcomes of linagliptin … Read More
SURPASS-6 Trial: Tirzepatide in T2DM
The SURPASS-6 trial, featured in JAMA in October 2023, represents a significant advancement in the treatment of type 2 diabetes. This randomized, phase 3, open-label trial was designed to evaluate the effects of once-weekly subcutaneous (SC) tirzepatide versus thrice-daily prandial … Read More
DIGAMI 2 Trial: Insulin-Based Glucose Control in Type 2 Diabetic Patients Following MI
DIGAMI 2 Trial Summary Introduction:The DIGAMI 2 trial aimed to evaluate the effect of insulin-based glucose control in type 2 diabetic patients following myocardial infarction compared to conventional management at similar levels of glucose control. The study investigated three treatment … Read More
AMPLITUDE-O Trial: CV and Renal Outcomes with Efpeglenatide
2021 AMPLITUDE-O TRIAL M Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes international, randomized, controlled trial Objective: To evaluate efpeglenatide in participants with type 2 diabetes and either a history of cardiovascular disease or current kidney disease 4076 … Read More
ADVANCE Trial Summary: Intensive Glucose Control in Diabetes Type 2
2008 ADVANCE TRIAL Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Multicenter, factorial, randomized trial Objective: To evaluate vascular effects of intensive glycemic therapy targeting a HbA1c <6.5% in patients with type II diabetes 11,140 … Read More
ACCORD Trial: Intensive Glucose Lowering in DM2
ACCORD: Effects of Intensive Glucose Lowering in Type 2 Diabetes Multicenter, double-blinded, two-by-two factorial, randomized controlled trial Objective: To assess if intensive glycemic control targeting a HbA1c <6% versus standard glycemic control targeting a HbA1c 7-7.9% reduce the risk of … Read More